LYRA - Lyra Therapeutics Inc Total Debt to Capital

Public company logo of Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics, Inc. (LYRA) brings together top-tier drug delivery specialists attracted by competitive compensation and the opportunity to achieve a breakthrough in otolaryngology. The business relies on the stable US legal environment, where ethical standards minimize political risks. The development of ENT products is based on the outsourcing of trials and manufacturing. This price chart reflects a total debt-to-equity ratio of 0.00.

LYRA: Lyra Therapeutics Total Debt to Capital 07/04/2022 - 03/28/2026

Analytical breakdowns for Lyra Therapeutics, Inc.

- price and consensus price forecast:
Price Chart Lyra Therapeutics|LYRA - Forecast Levels Chart
- market capitalization statistics:
Market Capitalization Lyra Therapeutics|LYRA - Value Adjusted for Debt and Cash
- book capitalization indicators:
Book Value per Share Lyra Therapeutics|LYRA - Book Capitalization|Market Value to Book Value Ratio lyratherapeutics.com|LYRA - Aggregate Asset Value
- company total debt and liquidity indicators:
Debt to Equity Lyra Therapeutics, Inc.|LYRA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Lyra Therapeutics, Inc.|LYRA - Company Aggregate Debts|Debt to Book Value Lyra Therapeutics|LYRA - Company Long-Term Loans and Borrowings|Company Short-Term Debt Lyra Therapeutics|Quick Liquidity Indicator lyratherapeutics.com
- earnings and valuation multiples information:
LYRA - Profit After Payment of Taxes
Basic company analysis:Lyra Therapeutics
Core merchandise of Lyra Therapeutics Inc

To build a resilient portfolio, I assess business dependence on creditors via the total liabilities-to-equity ratio, which determines the issuer's financial autonomy. In the case of Lyra Therapeutics, Inc. (LYRA), low leverage combined with the high pricing power of the unique XTreo matrix minimizes debt service risks, as evidenced by the stable ratio of debt to equity.

Competitor analysis for Lyra Therapeutics, Inc.

Debt to Equity Haleon|Kenvue Inc - Aggregate Debt to Equity|Total Debt to Capital VRNA|MENS (Jyong Bio) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital LGND (Ligand Pharmaceuticals)|Total Debt to Capital amneal.com AMRX|PRGO - Debt to Equity|All Debt to Shareholders' Equity Ratio ALVO (Alvotech S.A.)|Liquidia Technologies (LQDA) - Debt to Equity|Total Debt to Equity Ratio Galapagos Corp|ANIP (ANI Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital mannkindcorp.com|Total Debt to Equity Ratio AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Pharmaceuticals) - All Debt to Shareholders' Equity Ratio|Debt to Equity ARS Pharma SPRY|Theravance Corp (TBPH) - Debt to Capital|AQST: Total Debt to Equity Ratio|scPharmaceuticals Inc. - Aggregate Debt to Capital|TECX: Total Debt to Capital|Tonix Pharma - All Debt to Shareholders' Equity Ratio|SXTC (SXT Pharmaceuticals) - Total Debt to Capital|Debt to Capital Eupraxia Pharma EPRX|Debt to Equity BioHarvest Sciences (BHST)|EXOZ (invizyne.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Oramed Pharmaceuticals Inc. ORMP|Entera Bio Ltd - Debt to Equity|HYFT: Total Debt to Equity Ratio|Debt to Capital ABVC BioPharma, Inc|Cumberland Pharmaceuticals (CPIX) - Debt to Equity|quantumbiopharma.com - All Debt to Shareholders' Equity Ratio|FGEN (FibroGen) - Total Debt to Capital|Total Debt to Capital Telomir Pharmaceuticals Inc|Total Debt to Equity Ratio RANI (Rani Therapeutics)|SNYR (synergychc.com) - All Debt to Shareholders' Equity Ratio|Rallybio - Total Debt to Equity Ratio|Aggregate Debt to Capital LEXX (Lexaria Bioscience Corp)|Pulmatrix - Total Debt to Capital|All Debt to Shareholders' Equity Ratio PTHL (Pheton Holdings Ltd)|APM: Total Debt to Capital|Debt to Capital Impact BioMedical, Inc. (IBO)|Debt to Equity TNF Pharmaceuticals Inc.|YCBD: All Debt to Shareholders' Equity Ratio|Total Debt to Capital PRFX|Total Debt to Capital altamiratherapeutics.com (CYTO)|Debt to Equity Lipella LIPO|OPTN (OptiNose Corp) - Aggregate Debt to Equity|Pieris Pharmaceuticals - Total Debt to Capital|Debt to Capital procapsgroup.com|PTPI (Petros Pharmaceuticals, Inc.) - Total Debt to Equity Ratio|Qilian International Holding Group (QLI) - Total Debt to Capital|Total Debt to Equity Ratio SLRN|TFFP (TFF Pharmaceuticals, Inc) - Aggregate Debt to Capital